To improve life during and beyond sedation
Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to making inhaled sedation a standard therapy in intensive care.More about us
Bringing inhaled sedation to intensive care
We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.
Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.
By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.
*formerly known as AnaConDa
Our vision is for inhaled sedation to be a global standard therapy for patients in intensive care.
To achieve this, we will through clinical research pave the way for a paradigm shift in sedation in the intensive care.
Our research aims at a greater understanding of and increased knowledge about inhaled sedation, leading to medical advances for the benefit of patients in intensive care.
We also believe in working in partnerships – through various initiatives and research projects – that can lead to continued development and meaningful improvement for both patients and the healthcare system.
Committed to change the standard of care, with commercial progress and a strong balance sheet.
Sedana Medical AB (publ) plans to present its interim report for the second quarter 2022 in an audio…